Mendus AB (publ)

Thank you, everybody, for joining the 26Q1 webcast.

Hello, everyone.

So to start with the summary of Q1, we've had a very ambitious plan that we communicated end of last year that was based on the positive data that we have documented over time, including the long-term follow-up we presented end of last year of the ADVANCE2 trial that showed long-term survival in MRD-positive high-risk AML with now already nine patients beyond five years of survival. So that provided the basis for us to continue the development of the product. We are currently in a trial in a similar setting, but in combination with a drug called oral azacitidine. This is applied after high-intensity chemotherapy. The trial is called AML. 22 cadence trial or in short, the cadence trial for which we wish to recruit 20 patients in the first half of 2026. It's a bit of a bumpy recruitment in AML always. Also in this trial, we are now at 16 patients recruited and we're still aiming for 20 patients in the first half of this year, which will allow us to do a first readout of the trial. The preparations for the DIVA trial, which is in combination with less intensive first-line treatment of venetoclax and azacitidin, is on track. We will also explain in a bit more detail why this is relevant and how this positions us in the AML landscape. And for that trial, to support that trial, we have signed a contract with Helicia Newton-John Cancer Research Institute, which is the leading cancer research institute in Australia. As some of you may know, we are running multiple trials in Australia, and we've therefore also set up a daughter company called Mendes Australia, which is handling not only the practical parts and the trials in Australia, but also allows us to benefit from a very attractive tax incentive that the Australian government allows for companies like us that do their research in Australia. It's not the main reason. We do our trials in Australia. The main reason is we can work there with the best people. And in this case, particularly a professor called Andrew Wei, who has been paving the road for post-remission therapies and also for venetoclax in AML. But it's good to build out our presence in Australia to also allow for the very beneficial circumstances to run these trials. Then what we have. added as an indication to our myeloid blood cancer program is CML. CML is a very large field, roughly 10 times bigger than AML. It's in principle under control with drugs called TKIs or tyrosine kinase inhibitors, but the quality of life of patients can be heavily affected by the continued use of these TKIs. So we have set out the clinical development strategy to position VD-DenCell as an immunotherapy in CML and help more CML patients accomplish what you call treatment-free remission, where they can live a healthy life without being dependent on day-to-day TKIs. We are very happy that we obtained all the regulatory approvals for the phase one trial that we start with this program, the vital CML trial, marking therefore also the start of the Vita Densa clinical development in CML. And that trial is now ongoing and recruited the first patients already in Bergen in Norway. With that, I'd like to hand it over to Lotta for the financial summary.